Analytical Data
-
Gene name
PAGE4
- Application
-
Alternative Names
PAGE4; GAGEC1; JM27P antigen family member 4; PAGE-4; G antigen family C member 1; PAGE-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60829
-
Expression Region
1-102 aa
-
AA Sequence
MSARVRSRSR GRGDGQEAPD VVAFVAPGES QQEEPPTDNQ DIEPGQEREG TPPIEERKVE GDCQEMDLEK TRSERGDGSD VKEKTPPNPK HAKTKEAGDG QP
-
Molecular Weight
11.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAGE4 (Pseudogene in the PAGE family 4) is a member of the PAGE family of proteins that has garnered significant attention in the field of cancer immunology and therapeutic research. Originally identified as a cancer/testis antigen, PAGE4 is primarily expressed in various tumors and limited normal tissues, making it a potential target for cancer immunotherapy. The expression of PAGE4 in malignant cells suggests its role in tumorigenesis and provides an opportunity for developing targeted therapies that could harness the immune system to recognize and attack cancer cells. Recent studies have focused on characterizing the immunogenic properties of PAGE4, including the identification of specific epitopes that could be utilized in vaccine development. Additionally, researchers are exploring the mechanisms through which PAGE4 contributes to tumor growth and survival, as well as its potential interactions with other oncogenic pathways. The aim is to elucidate the functional role of PAGE4 in cancer progression and its potential as a biomarker for diagnosis and prognosis. Overall, the investigation of PAGE4 is set against the backdrop of a growing interest in cancer/testis antigens as promising candidates for novel immunotherapeutic strategies, with the goal of improving treatment outcomes for patients with various malignancies.
